title: Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease.
abstract: Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose). Five patients responded immediately to the first course of prednisolone infusion. One patient failed to respond to the first course of prednisolone therapy, but he did respond to the second 3-day course of therapy. None of the patients demonstrated a further progression of coronary artery dilatation or any adverse effects. Standard-dose and short-term corticosteroid therapy therefore appears to be a safe and effective treatment for patients with IVIG-resistant KD.
authors.affiliation: University of Shizuoka, Shizuoka 422-8021, Japan.
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Takeshita
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kawamura
authors.forename: Keigo
authors.initials: K
authors.lastname: Nakatani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsujimoto
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Tokutomi
mesh_terms: D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage*; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D011239:Prednisolone